BDTX-1535
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BDTX-1535, covering 2025-11-20 to 2025-11-20. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions [EARLY_Phase 1]